Real-time · AI · Cross-signal

FibroBiologics just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on FibroBiologics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

▶

Watch the 2-minute tour · with sound

FibroBiologics Engages Southern Star Research as CRO in Australia

Sep 19, 2024•over 1 year ago

Contract Type

partnership

HoustonBiotechnologyHealth CareTherapeutics

Description

FibroBiologics has engaged with Southern Star Research to provide clinical research organization (CRO) services in Australia, including preparatory work for a Phase 1/2 clinical trial utilizing product candidate, CYWC628, to treat diabetic foot ulcers. This partnership marks an important step forward in creating the infrastructure for FibroBiologics to conduct clinical trials in Australia.

Company Information

Company

FibroBiologics

Location

455 E. Medical Center Blvd, Suite 300

Houston, Texas, United States

About

FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for FibroBiologics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months